skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Kinetics of 3-(4-methylbenzylidene)camphor in rats and humans after dermal application

Journal Article · · Toxicology and Applied Pharmacology
 [1];  [1];  [2];  [2];  [2];  [2];  [1]
  1. Institute of Toxicology, University of Wuerzburg, Versbacherstrasse 9, 97078 Wuerzburg (Germany)
  2. Institute of Toxicology, Merck KGaA, 64271 Darmstadt (Germany)

The toxicokinetics of 4-MBC after dermal administration were investigated in human subjects and in rats. Humans (3 male and 3 female subjects) were exposed to 4-MBC by topical application of a commercial sunscreen formulation containing 4% 4-MBC (w/w), covering 90% of the body surface and resulting in a mean dermal 4-MBC dose of 22 mg/kg bw. In rats, dermal 4-MBC doses of 400 and 2000 mg/kg bw were applied in a formulation using an occlusive patch for 24 h. Concentrations of 4-MBC and its metabolites were monitored over 96 h in plasma (rats and humans) and urine (humans). In human subjects, plasma levels of 4-MBC peaked at 200 pmol/ml in males and 100 pmol/ml in females 6 h after application and then decreased to reach the limit of detection after 24 h (females), respectively, 36 h (males). After dermal application of 4-MBC, peak plasma concentrations of 3-(4-carboxybenzylidene)-6-hydroxycamphor were 50-80 pmol/ml at 12 h and of 3-(4-carboxybenzylidene)camphor were 100-200 pmol/ml at 24 h. In male and female rats, peak plasma levels of 4-MBC were 200 (dose of 400 mg/kg bw) and 1 200 pmol/ml (dose of 2000 mg/kg bw). These levels remained constant for up to 24-48 h after dermal application. Peak plasma concentrations of 3-(4-carboxybenzylidene)-6-hydroxycamphor were 18,000 pmol/ml (males) and of 3-(4-carboxybenzylidene)camphor were 55,000 pmol/ml (females) between 48 and 72 h after application of the high dose of 4-MBC. In human subjects, only a small percentage of the dermally applied dose of 4-MBC was recovered in the form of metabolites in urine, partly as glucuronides. The obtained results suggest a more intensive biotransformation of 4-MBC in rats as compared to humans after dermal application and a poor absorption of 4-MBC through human skin.

OSTI ID:
20850455
Journal Information:
Toxicology and Applied Pharmacology, Vol. 216, Issue 2; Other Information: DOI: 10.1016/j.taap.2006.05.011; PII: S0041-008X(06)00190-6; Copyright (c) 2006 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved; Country of input: International Atomic Energy Agency (IAEA); ISSN 0041-008X
Country of Publication:
United States
Language:
English

Similar Records

Toxicokinetics and biotransformation of 3-(4-methylbenzylidene)camphor in rats after oral administration
Journal Article · Sun Oct 15 00:00:00 EDT 2006 · Toxicology and Applied Pharmacology · OSTI ID:20850455

4,4'-Methylene-bis(2-chloroaniline) (MOCA): Comparison of macromolecular adduct formation after oral or dermal administration in the rat
Journal Article · Thu Feb 01 00:00:00 EST 1990 · Fundamental and Applied Toxicology; (USA) · OSTI ID:20850455

Low-Dose Pharmacokinetics and Oral Bioavailability of Dichloroacetate in Naive and GST-zeta Depleted Rats
Journal Article · Tue Jan 01 00:00:00 EST 2002 · Environmental Health Perspectives · OSTI ID:20850455